Unfulfilled Promises: Senate Report Reveals Rising Drug Prices Despite Trump's Pledges
President Donald Trump's promises to lower prescription drug prices in the U.S. through deals with drugmakers have not been fulfilled, as prices have continued to rise, according to a report released by Senate Democrats. The report, spearheaded by Sen. Bernie Sanders, revealed that companies that signed deals with Trump have increased the prices of hundreds of medications, including gene therapies, cancer drugs, and multiple sclerosis treatments. These companies have also seen significant profits during Trump's second term in office, raising concerns about the impact on patients.
Health Secretary Robert F. Kennedy Jr. is expected to testify on Trump's budget and priorities, including lowering drug costs. The report questions the effectiveness of the administration's drug pricing deals, known as "most favored nation" agreements, in reducing prices for patients. Despite the lack of transparency surrounding these deals, the report highlights the rising list prices of blockbuster drugs, such as Keytruda, Kesimpta, and Opdivo, in the U.S. compared to other countries.
While drugmakers offered discounted prices on TrumpRx.gov for cash-paying customers, the list prices of many medications continued to climb. The report emphasized the disparity in drug prices between the U.S. and other countries, raising concerns about affordability and access to essential medications. The lack of comprehensive price reductions across drug portfolios covered by the deals has led to ongoing price hikes for many drugs not included in the agreements.
The report also highlighted the launch of new high-priced medications, particularly cancer drugs, by companies that negotiated deals with Trump. Despite efforts to address drug pricing, the report suggests that the Biden administration's policies, such as Medicare drug pricing negotiations, have had a more significant impact on lowering list prices. The findings underscore the ongoing challenges in addressing rising prescription drug costs and the need for comprehensive solutions to ensure affordable access to vital medications.